Indian pharma company Sun Pharmaceuticals Industries announced that it has received regulatory nod from the Drug Controller General of India (DCGI) to manufacture and sell the generic version of weight-loss drug Wegovy. The product received regulatory approval from the DCGI following a review of its Phase III clinical trial conducted in India.
The company will launch and market a generic version of semaglutide injection. The latter is a glucagon-like peptide-1 (GLP-1) receptor agonist, which is indicated for the long-term management of body weight in adults when used alongside a reduced-calorie diet and increased physical activity.
Generic semaglutide is the active ingredient in Novo Nordisk’s drugs Wegovy and Ozempic.
About the Product
The drugmaker will launch generic semaglutide injection in India under the brand name Noveltreat, after the expiry of its semaglutide patent in March 2026.
Noveltreat will be available in five dose strengths:
0.25 mg/0.5 mL,
0.5 mg/0.5 mL,
1 mg/0.5 mL,
1.7 mg/0.75 mL,
2.4 mg/0.75 mL.
The 2.4 mg dose will also be available as the once-weekly maintenance dose. The product will be administered via a prefilled pen, which will help support convenient and accurate dosing, the company added.
Commenting on this regulatory win, Kirti Ganorkar, Managing Director, Sun Pharma, said, “Noveltreat meets global quality standards and is supported by robust Indian clinical evidence on efficacy and safety for weight management. As India’s largest pharmaceutical company with leadership in cardiometabolic therapies, we are committed to improving access to generic semaglutide across the country after the patent expiry.”
Sun Pharma second drugmaker to get regulatory nod
With this authorisation, Sun Pharma becomes the second Indian drugmaker to receive regulatory approval for generic semaglutide, following Dr. Reddy’s Laboratories, which last week received regulatory nod for selling the diabetes drug Ozempic.
Sun Pharma share price movement
The share price of Sun Pharma was trending flat in the early trade session. Over the past one month, the company’s stock has declined by over 7%. Meanwhile, the share price of its competitor Dr Reddy’s was up over 2% in the early trade session. Over the past one month, the company’s stock has declined by nearly 3%.